[ET Net News Agency, 29 May 2019] Sihuan Pharmaceutical Holdings Group Ltd. (00460)
said that the third generation of EGFR inhibitor XZP-5809 (the new drug), a Category 1
innovative drug developed by the group, has been granted drug clinical trial approval by
the National Medical Products Administration of the PRC.
The new drug is a novel third-generation epithelial growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI) that has strong targeting capability. It can be taken orally.
It features innovative structure, established mechanism and irreversible binding to EGFR.
(RC)